Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

Micro-Abstract The incidence of acute myeloid leukemia (AML) increases with age, with poor prognosis in older patients. We report findings from a dose-escalation study of barasertib, an Aurora B kinase inhibitor, plus low-dose cytosine arabinoside (LDAC) in 22 AML patients aged 60 years or older. Th...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2013-10, Vol.13 (5), p.559-567
Main Authors: Kantarjian, Hagop M, Sekeres, Mikkael A, Ribrag, Vincent, Rousselot, Philippe, Garcia-Manero, Guillermo, Jabbour, Elias J, Owen, Kate, Stockman, Paul K, Oliver, Stuart D
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Barasertib-hQPA
Cytarabine - administration & dosage
Cytarabine - pharmacokinetics
Dose-escalation study
Female
Hematology, Oncology and Palliative Medicine
Humans
Leukemia, Myeloid, Acute - drug therapy
Male
Middle Aged
Organophosphates - administration & dosage
Organophosphates - pharmacokinetics
Quinazolines - administration & dosage
Quinazolines - pharmacokinetics
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract The incidence of acute myeloid leukemia (AML) increases with age, with poor prognosis in older patients. We report findings from a dose-escalation study of barasertib, an Aurora B kinase inhibitor, plus low-dose cytosine arabinoside (LDAC) in 22 AML patients aged 60 years or older. The maximum tolerated dose (MTD) of barasertib was 1000 mg. A preliminary overall response rate of 45% was reported.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2013.03.019